Sehouli J - Search Results

1

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N. Ray-Coquard I, et al. Among authors: sehouli j. Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019. Front Oncol. 2019. PMID: 31552170 Free PMC article.

2

First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.

Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W; Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Gynecol Oncol. 2002 May;85(2):321-6. doi: 10.1006/gyno.2002.6623. Gynecol Oncol. 2002. PMID: 11972395 Clinical Trial.

3

Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer.

Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L, Zeimet AG. Marth C, et al. Among authors: sehouli j. Cancer. 2007 Feb 15;109(4):645-9. doi: 10.1002/cncr.22467. Cancer. 2007. PMID: 17238177 Free article. Review. No abstract available.

4

Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.

Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Hefler LA, et al. Among authors: sehouli j. Clin Cancer Res. 2008 Feb 1;14(3):710-4. doi: 10.1158/1078-0432.CCR-07-1044. Clin Cancer Res. 2008. PMID: 18245530

5

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W. Sehouli J, et al. J Clin Oncol. 2008 Jul 1;26(19):3176-82. doi: 10.1200/JCO.2007.15.1258. J Clin Oncol. 2008. PMID: 18591555 Clinical Trial.

6

Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.

Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology. Sehouli J, et al. Cancer Chemother Pharmacol. 2009 Aug;64(3):585-91. doi: 10.1007/s00280-008-0909-1. Epub 2009 Jan 21. Cancer Chemother Pharmacol. 2009. PMID: 19156414

7

A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.

Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. Vergote I, et al. Among authors: sehouli j. Eur J Cancer. 2009 May;45(8):1415-23. doi: 10.1016/j.ejca.2008.12.013. Epub 2009 Jan 23. Eur J Cancer. 2009. PMID: 19168349 Clinical Trial.

8

Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.

Mahner S, Woelber L, Jung S, Eulenburg CZ, Ihnen M, Schwarz J, Sehouli J, Jaenicke F. Mahner S, et al. Among authors: sehouli j. Anticancer Res. 2009 Jul;29(7):2817-21. Anticancer Res. 2009. PMID: 19596967 Free article.

9

Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.

Vergote I, Amant F, Oskay-Oezcelik G, Musib L, Michel AL, Darstein C, Kania M, Bauknecht T, Sehouli J. Vergote I, et al. Among authors: sehouli j. Int J Gynecol Cancer. 2009 Dec;19(9):1505-10. doi: 10.1111/IGC.0b013e3181bda1a7. Int J Gynecol Cancer. 2009. PMID: 19955926 Clinical Trial.

10

Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.

Oskay-Ozcelik G, Chekerov R, Sommer H, Keil E, Einenkel J, Pfisterer J, Lorenz-Schlüter C, Lichtenegger W, Camara O, Sehouli J. Oskay-Ozcelik G, et al. Among authors: sehouli j. Gynecol Oncol. 2010 Mar;116(3):317-22. doi: 10.1016/j.ygyno.2009.09.031. Epub 2009 Dec 2. Gynecol Oncol. 2010. PMID: 19959213 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

766 results

Search Page